Home   >  

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials

Wnt/Stem Cell

Chemical Structure Cat. No. Product Name CAS No.
QL-1200186 Chemical Structure
BCP49631 QL-1200186 2848664-42-4
QL-1200186 is an orally active and selective TYK2 inhibitor.
BMS-986115 Chemical Structure
BCP49196 BMS-986115 1584647-27-7
BMS-986115 is a potent Notch inhibitor, with IC50s of 7.8 and 8.5 nM for Notch 1 and Notch 3, respectively.
LP-922056 Chemical Structure
BCP28623 LP-922056 1365060-22-5
LP-922056 is a Notum pectinacetylesterase inhibitor which activates wnt signalling. LP-922056 increases cortical bone thickness in a mouse model of bone growth.
Filgotinib maleate Chemical Structure
BCP49095 Filgotinib maleate 1802998-75-9
Filgotinib maleate is a potent and selective JAK1 inhibitor under investigation for the treatment of rheumatoid arthritis (RA) and Crohn's disease.
Solcitinib Chemical Structure
BCP23893 Solcitinib 1206163-45-2
Solcitinib is a Janus kinase 1 (JAK1) inhibitor. Solcitinib may be potential useful for treatment of psoriasis,systemic lupus erythematosus, ulcerative colitis.
Oct3/4-inducer-1 Chemical Structure
BCP24154 Oct3/4-inducer-1 1016535-83-3
MDK35833, also known as Oct3/4-inducer-1, is a potent Oct3/4 inducer. Oct3/4-inducer-1 promotes expression and stabilization of Oct3/4, and enhances its transcriptional activity in diverse human somatic cells.
Nirogacestat Chemical Structure
BCP24479 Nirogacestat 1290543-63-3
Nirogacestat is a potent and selective gamma secretase (GS) inhibitor with potential antitumor activity. PF-03084014 binds to GS, blocking proteolytic activation of Notch receptors. Nirogacestat enhances the Antitumor Effect of Docetaxel in Prostate Cancer. Nirogacestat enhances docetaxel-mediated tumor response and provides a rationale to explore GSIs as adjunct therapy in conjunction with docetaxel for men with CRPC (castration-resistant prostate cancer).
Pacritinib citrate Chemical Structure
BCP48998 Pacritinib citrate 1228923-42-9
Pacritinib Citrate is the citrate salt form of pacritinib, an orally bioavailable inhibitor of Janus kinase 2 (JAK2), the JAK2 mutant JAK2V617F and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity.
HA-100 dihydrochloride Chemical Structure
BCP48930 HA-100 dihydrochloride 210297-47-5
HA-100 dihydrochloride is a protein kinase inhibitor, inhibiting superoxide release from human neutrophils (PMN).
(E/Z)-GSK-3β inhibitor 1 Chemical Structure
BCP48909 (E/Z)-GSK-3β inhibitor 1 3367-88-2
(E/Z)-GSK-3β inhibitor 1 is a racemic compound of (E)-GSK-3β inhibitor 1 and (Z)-GSK-3β inhibitor 1 isomers.
123下一页末页共 402 条记录 1 / 41 页